Design principles for bacteria-responsive antimicrobial nanomaterials
Source abstract
Abstract
Abstract Despite advancements in biomedical sciences and medicine, bacterial infection remains a leading cause of death globally. The conventional treatment of bacterial infections through general administration of antibiotics has been challenged by the emergence of antibiotics resistance. An exciting direction to solve current challenges that attracted enormous interest in the last decade is focused on designing stimuli-responsive systems incorporating a wide range of antimicrobial nanomaterials. The aim of this review is to highlight fundamental principles involved in the design of bacteria-responsive nanosystems that release their antibacterial load in response only to the specific environment and factors produced endogenously by bacteria. Such specific changes to the micro-environment include changes in pH, reactive oxygen species, and production of enzymes specific to bacteria. We provide examples and a critical review of such systems and finish with the authors’ perspective for the future of the field.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Graphene and Nanomaterials Applications · Bacterial biofilms and quorum sensing
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications10.1016/j.jconrel.2014.12.030 ↗
2. Epigenetics advancing personalized nanomedicine in cancer therapy10.1016/j.addr.2012.08.004 ↗
3. Phage-enabled nanomedicine: from probes to therapeutics in precision medicine10.1002/anie.201606181 ↗
4. Breaking down the barriers to precision cancer nanomedicine10.1016/j.tibtech.2016.07.006 ↗
5. Robotic surgery10.1002/bjs.9711 ↗
6. Personalized nanomedicine advancements for stem cell tracking10.1016/j.addr.2012.07.008 ↗
7. Advancement in cardiac imaging for treatment of ventricular arrhythmias in structural heart disease
8. Nanomedicine10.1039/c2cs90005j ↗
9. Nanomedicine 2.010.1021/acs.accounts.6b00629 ↗
10. Bacterial infection microenvironment-responsive enzymatically degradable multilayer films for multifunctional antibacterial properties10.1039/C7TB02114C ↗
11. Nanoparticle-based local antimicrobial drug delivery10.1016/j.addr.2017.09.015 ↗
12. 2018
13. Changing patterns of infectious disease10.1038/35021206 ↗
14. The bacteria fight back10.1126/science.321.5887.356 ↗
15. 2019
16. Antimicrobial resistance: tackling a crisis for the health and wealth of nations
17. A brief history of the antibiotic era: lessons learned and challenges for the future10.3389/fmicb.2010.00134 ↗
18. Shifting the balance: antibiotic effects on host–microbiota mutualism10.1038/nrmicro2536 ↗
19. The future challenges facing the development of new antimicrobial drugs10.1038/nrd940 ↗
20. Nanomaterials for targeted detection and photothermal killing of bacteria10.1039/c2cs15340h ↗
21. Antimicrobial resistance: priorities for action10.1093/jac/49.4.585 ↗
22. Antibiotic resistance and its cost: is it possible to reverse resistance?10.1038/nrmicro2319 ↗
23. The antibiotics market10.1038/nrd3267 ↗
24. Molecular mechanisms of antibiotic resistance10.1039/c0cc05111j ↗
25. Global contributors to antibiotic resistance10.4103/jgid.jgid_110_18 ↗
26. “Nanoantibiotics”: a new paradigm for treating infectious diseases using nanomaterials in the antibiotics resistant era10.1016/j.jconrel.2011.07.002 ↗
27. Nanomaterials for alternative antibacterial therapy10.2147/IJN.S132163 ↗
28. Antibiotic-free antibacterial strategies enabled by nanomaterials: progress and perspectives10.1002/adma.201904106 ↗
29. The antimicrobial activity of nanoparticles: present situation and prospects for the future10.2147/IJN.S121956 ↗
30. Nanomaterials with active targeting as advanced antimicrobials10.1002/wnan.1636 ↗
31. Recent advances in functionalized nanomaterials for the diagnosis and treatment of bacterial infections10.1016/j.msec.2020.111843 ↗
32. Nanomaterials as promising alternative in the infection treatment10.3390/ijms20153806 ↗
33. Silver-based wound dressings: Current issues and future developments for treating bacterial infections
34. Responsive and “smart” antibacterial surfaces: common approaches and new developments (Review)10.1116/1.4866697 ↗
35. Antibacterial surfaces for biomedical devices10.1586/erd.09.36 ↗
36. Stimuli-responsive polymers: biomedical applications and challenges for clinical translation10.1016/j.addr.2012.11.004 ↗
37. Stimuli-responsive nanocarriers for drug delivery10.1038/nmat3776 ↗
38. Design of smart targeted and responsive drug delivery systems with enhanced antibacterial properties10.1039/C8NR07146B ↗
39. Recent developments in smart antibacterial surfaces to inhibit biofilm formation and bacterial infections10.1039/C8TB01245H ↗
40. Bacterial hyaluronidase self-triggered prodrug release for chemo-photothermal synergistic treatment of bacterial infection10.1002/smll.201601729 ↗
41. Antifouling and tunable amino functionalized porous membranes for filtration applications10.1039/c2jm34172g ↗
42. H2O2-responsive theranostic nanomedicine10.1016/j.cclet.2017.05.023 ↗
43. Construction of high drug loading and enzymatic degradable multilayer films for self-defense drug release and long-term biofilm inhibition10.1021/acs.biomac.7b01268 ↗
44. Bacterial self-defense antibiotics release from organic–inorganic hybrid multilayer films for long-term anti-adhesion and biofilm inhibition properties10.1039/C7NR07106J ↗
45. Bacterial lipases from Pseudomonas: regulation of gene expression and mechanisms of secretion10.1016/S0300-9084(00)01182-2 ↗
46. Triggered release of bacteriophage K from agarose/hyaluronan hydrogel matrixes by Staphylococcus aureus virulence factors10.1021/cm503974g ↗
47. Hyaluronidases of gram-positive bacteria10.1111/j.1574-6968.2000.tb08958.x ↗
48. Lipase-sensitive polymeric triple-layered nanogel for “on-demand” drug delivery10.1021/ja211279u ↗
49. Bacteria-triggered release of antimicrobial agents10.1002/anie.201307975 ↗
50. Enzyme responsive hyaluronic acid nanocapsules containing polyhexanide and their exposure to bacteria to prevent infection10.1021/bm302003m ↗
51. Bacteria-responsive multifunctional nanogel for targeted antibiotic delivery10.1002/adma.201202847 ↗
52. Antibacterial plasma polymer films conjugated with phospholipid encapsulated silver nanoparticles10.1021/acsbiomaterials.5b00338 ↗
53. Biodegradable polycation and plasmid DNA multilayer film for prolonged gene delivery to mouse osteoblasts10.1016/j.biomaterials.2007.10.033 ↗
54. Manipulating extracellular tumour pH: an effective target for cancer therapy10.1039/C8RA02095G ↗
55. Roles of pH in control of cell proliferation10.1111/apha.13068 ↗
56. Surface-adaptive gold nanoparticles with effective adherence and enhanced photothermal ablation of methicillin-resistant Staphylococcus aureus biofilm10.1021/acsnano.7b04731 ↗
57. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?10.1038/nrd2803 ↗
58. Recent progress in the biological applications of reactive oxygen species-responsive polymers10.1080/15583724.2019.1641515 ↗
59. Reactive oxygen species: from health to disease10.4414/smw.2012.13659 ↗
60. Enhancement of reactive oxygen species production and chlamydial infection by the mitochondrial Nod-like family member NLRX110.1074/jbc.M110.137885 ↗
61. Smoldering and polarized inflammation in the initiation and promotion of malignant disease10.1016/j.ccr.2005.02.013 ↗
62. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR410.1016/j.ccr.2012.02.007 ↗
63. Gut microbes define liver cancer risk in mice exposed to chemical and viral transgenic hepatocarcinogens10.1136/gut.2009.183749 ↗
64. Pathogenic intestinal bacteria enhance prostate cancer development via systemic activation of immune cells in mice10.1371/journal.pone.0073933 ↗
65. Gut bacteria require neutrophils to promote mammary tumorigenesis10.18632/oncotarget.3328 ↗
66. Constitutively active DNA damage checkpoint pathways as the driving force for the high frequency of p53 mutations in human cancer10.1016/j.dnarep.2004.03.036 ↗
67. An oncogene-induced DNA damage model for cancer development10.1126/science.1140735 ↗
68. Genomic instability—an evolving hallmark of cancer10.1038/nrm2858 ↗
69. Clonal evolution in cancer10.1038/nature10762 ↗
70. Bacterial genotoxins: the long journey to the nucleus of mammalian cells10.1016/j.bbamem.2015.08.016 ↗
71. Hallmarks of cancer: the next generation10.1016/j.cell.2011.02.013 ↗
72. Escherichia coli induces DNA double-strand breaks in eukaryotic cells10.1126/science.1127059 ↗
73. A bacterial toxin that controls cell cycle progression as a deoxyribonuclease I-like protein10.1126/science.290.5490.354 ↗
74. Shiga toxin 1: damage to DNA in vitro10.1016/S0041-0101(00)00135-5 ↗
75. Restriction endonucleases from invasive Neisseria gonorrhoeae cause double-strand breaks and distort mitosis in epithelial cells during infection10.1371/journal.pone.0114208 ↗
76. Delivery of antibiotics with polymeric particles10.1016/j.addr.2014.02.002 ↗
77. Bacterial biofilms: a common cause of persistent infections10.1126/science.284.5418.1318 ↗
78. The in vivo biofilm10.1016/j.tim.2013.06.002 ↗
79. Biofilms as complex differentiated communities10.1146/annurev.micro.56.012302.160705 ↗
80. Regulation of autolysis-dependent extracellular DNA release by Enterococcus faecalis extracellular proteases influences biofilm development10.1128/JB.00314-08 ↗
81. Viscoelasticity of biofilms and their recalcitrance to mechanical and chemical challenges10.1093/femsre/fuu008 ↗
82. The biofilm matrix10.1038/nrmicro2415 ↗
83. Nanotechnology as a therapeutic tool to combat microbial resistance10.1016/j.addr.2013.07.011 ↗
84. Recent advances in thromboresistant and antimicrobial polymers for biomedical applications: just say yes to nitric oxide (NO)10.1039/C6BM00271D ↗
85. A review of current and emergent biofilm control strategies10.1016/j.lwt.2009.12.008 ↗
86. Advances in industrial biofilm control with micro-nanotechnology
87. New strategies in the development of antimicrobial coatings: the example of increasing usage of silver and silver nanoparticles10.3390/polym3010340 ↗
88. Antibacterial properties of nanoparticles10.1016/j.tibtech.2012.06.004 ↗
89. Bacterial biofilms: from the Natural environment to infectious diseases10.1038/nrmicro821 ↗
90. Should we stay or should we go: mechanisms and ecological consequences for biofilm dispersal10.1038/nrmicro2695 ↗
91. Bioinspired implant materials befuddle bacteria
92. Ecological advantages of autolysis during the development and dispersal of Pseudoalteromonas tunicata biofilms10.1128/AEM.00546-06 ↗
93. Dispersal from microbial biofilms10.1128/9781555817466.ch17 ↗
94. Cell death in Pseudomonas aeruginosa biofilm development10.1128/JB.185.15.4585-4592.2003 ↗
95. Biofilm development and cell death in the marine bacterium Pseudoalteromonas tunicata10.1128/AEM.70.6.3232-3238.2004 ↗
96. Phenotypic differentiation and seeding dispersal in non-mucoid and mucoid Pseudomonas aeruginosa biofilms10.1099/mic.0.27536-0 ↗
97. Cyclic di-GMP: the first 25 years of a universal bacterial second messenger10.1128/MMBR.00043-12 ↗
98. You’ve come a long way: c-di-GMP signaling10.1016/j.mib.2011.12.008 ↗
99. Direct evaluation of Pseudomonas aeruginosa biofilm mediators in a chronic infection model10.1128/IAI.00057-11 ↗
100. Clearance of Pseudomonas aeruginosa foreign-body biofilm infections through reduction of the cyclic di-GMP level in the bacteria10.1128/IAI.00332-13 ↗